Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
The live and archived webcast of the panel will be accessible from the company's website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.InvestorsJoshua Higa ir@ultragenyx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
12 minutes ago
- Wall Street Journal
Heard on the Street Tuesday Recap: Big Tech Stumbles, Markets Fall
Tech weighs on the market. A drop in megacap technology stocks pushed major indexes into the red. The eight companies valued at more than $1 trillion lost a combined $385 billion in market capitalization. The Nasdaq Composite closed down 1.5%. Valuations chipped away. More expensive tech names saw even greater pressure. Palantir, which trades at more than 200 times projected earnings, led S&P 500 decliners with a 9.4% drop. Oracle dropped 5.8%.
Yahoo
43 minutes ago
- Yahoo
Bitcoin Drops Below $114K, Ether Loses $4.2K as Jackson Hole Speech Might Bring Hawkish Surprise
Cryptocurrencies continued their slide on Tuesday with bitcoin (BTC) sinking below $114,000 as investors are turning cautious that Federal Reserve Chair Powell's Friday Jackson Hold speech may come with a hawkish surprise. BTC dropped to $113,700 during the early hours of the U.S. session, its weakest price in almost two weeks and pulling back 9% from its Thursday record high above $124,000. Ether (ETH) slid 3.5% over the past 24 hours below $4,200. Major altcoins weren't spared either: Chainlink (LINK), Avalanche (AVAX), Toncoin (TON), Ethena (ENA) and Aptos (APT) declined 4%-6% in a day. The crypto pullback occurred alongside with traditional markets turning risk-off, with Nasdaq and S&P 500 indexes down 0.9% and 0.4%, respectively, in the morning. A check of crypto treasury companies shows that bubble continuing to deflate, with BTC accumulator KindlyMD (NAKA) lower by another 14% on Tuesday. ETH-focused names Bitmine Immersion (BNMR) and Sharplink Gaming (SBET) are down 10% and 8%, respectively. Since soaring as high as $124 in late May in wake of its transition to an ether treasury strategy company, SBET — to pick one — has now crumbled by about 85% to its current $18.60. The grandaddy of the group — Michael Saylor's Strategy (MSTR) was down 5.7% on Tuesday, now lower by 20% over the past month and off 37% from a record high hit late last year. Shares, of course, remain up more than 20-fold since Saylor began purchasing BTC about five years ago. Being the first mover has its advantages. Investors, who previously saw a September interest rate cut by the Federal Reserve as a given, are now weighing the odds that Fed Chair Jerome Powell might argue for holding rates steady during his Friday keynote address at the Kansas City Fed's Economic Symposium. Despite recent signs of a weakening job market and slowing economy, last week's far hotter-than-expected PPI report reignited concerns of inflation reaccelerating. Economists at Bank of America said in a report that they see the Fed holding rates in September. "With inflation essentially stuck over the past year, the tariff pass-through that we still expect, and the labor supply story keeping the unemployment rate historically low, we still think there is a strong case for the Fed to remain on hold," the analysts said. Market participants put a 85% likelihood of 25 basis point cut next month, down from as high as 98% at one point last week, according to the CME FedWatch Tool. 登入存取你的投資組合
Yahoo
an hour ago
- Yahoo
Meet the Monster Stock That Continues to Crush the Market
Key Points Palantir has been seeing accelerating revenue growth as customers adopt its AI platform. While the stock is pricey, it has an enormous opportunity still in front of it. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) has been the single best-performing stock in the not just this year, but last year as well. The artificial intelligence (AI) leader more than doubled in 2025 through mid-August, on top of a stunning 340% gain in 2024. That kind of back-to-back performance is almost unheard of, and it's no accident. The company is growing at a blistering pace, landing massive new contracts and rapidly expanding the reach of its Artificial Intelligence Platform (AIP). With momentum this strong, it's worth looking at exactly what's driving the surge, what could slow it down, and why the long-term opportunity remains enormous. What Palantir does Palantir made a name for itself in the years after 9/11, providing advanced data analytics to U.S. intelligence agencies. It built a reputation for solving complex, high-stakes problems, with the government using it to fight terrorism and later track COVID cases. The U.S. federal government remains Palantir's largest customer, but its biggest growth engine is now the commercial sector. Palantir's secret sauce is AIP. The solution collects data from a multitude of sources, organizes it into what it calls an "ontology," and connects it to real-world assets and processes. This gives AI models the clean source of data they need to help solve real-world problems. Palantir is not building large language models (LLMs), instead it is providing the system that gives organizations the tools to make AI actually work. In essence, AIP is like an AI operating system. Strong growth Palantir's results speak for themselves. The company has seen its revenue growth accelerate for eight straight quarters. In Q2, its revenue soared 48% year over year to $1 billion. U.S. commercial revenue jumped 93% to $306 million, with customer count up 43% from a year ago. Remaining deal value in that segment more than doubled to $2.79 billion, showing just how quickly adoption is growing. Existing customers are also expanding quickly, with net dollar retention climbing to 128%. (Any number north of 100% means a company saw growth from existing customers, net of any churn.) The government side is equally strong. U.S. government revenue surged 53% to $426 million in Q2, and Palantir landed a 10-year, $10 billion Army contract consolidating 75 agreements into one. International government sales grew 37%. Risks No stock is risk-free, and the most obvious risk for Palantir is its valuation. The stock trades at a forward price-to-sales (P/S) ratio of nearly triple digits, and its price-to-earnings (P/E) multiple is nearing 275. Even if the stock were cut in half, it would still be far from cheap. That means expectations for the stock are sky high, and any slowdown in growth or hiccup in execution could send shares tumbling. International commercial adoption remains a weak spot, with revenue in that segment down slightly last quarter, so the company still has work to do in proving it can scale globally outside its government and U.S. commercial strongholds. And while the company hasn't felt an impact from U.S. government spending cuts, other defense contractors have, so it is still something to at least keep an eye on. The massive opportunity ahead Despite those risks, Palantir's opportunity is hard to ignore. AIP appears to be a game-changing platform for Palantir, capable of providing real-world analysis across seemingly any industry. The breadth of use cases for AIP is just incredible; it's being used for everything from monitoring sepsis at hospitals to helping insurance companies with their underwriting to helping companies with their supply chains. Many customers are still in the early stages of deployment, which means the opportunity for increased usage and more use cases within these customers is a huge opportunity. The company is also rolling out AI agents that can take even more direct action and handle specific automated tasks, which could further increase the platform's stickiness and impact. And with European commercial markets largely untapped, Palantir has another major growth lever. Palantir's stock is pricey, although great companies rarely trade at bargain prices. If it can maintain its AI leadership position and continue expanding its reach, the stock has the potential to be one of the defining AI investments of the next decade. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Meet the Monster Stock That Continues to Crush the Market was originally published by The Motley Fool Sign in to access your portfolio
